The China-Nvidia Chip Deal Is Even Dumber Than You Think - National Review

The fundamental absurdity of this arrangement: it manufactures a technical dead zone. The chip is deliberately capped below frontier training thresholds yet above compliance red lines—useful to no one, satisfying no one. This is strategic miscalculation wearing a trade costume. Technical cascade: The H20-class compromise shatters Nvidia's CUDA value proposition in the Chinese market. Domestic AI labs, forced to rebuild inference stacks on adequate-but-inefficient silicon, are accelerating operator-library localization. Upstream, CoWoS advanced-packaging utilization in Taiwan, China faces fragmentation pressure. Downstream, Huawei's Ascend 910B/C gains an unexpected window—when Nvidia voluntarily drags its product into mid-tier, the domestic cost-performance narrative suddenly holds. Compliance risk: Nvidia's compliance theater—per-chip export licenses, end-user tracking, re-export restrictions—now consumes over 30% of gross margin on the China line. Worse, the architecture itself is a legal target: one policy tweak can turn shipped inventory into a liability overnight. Market dynamics: AMD's MI300X has near-zero China presence, yet Nvidia's self-castration hands AMD the full-performance differentiation. The deeper variable is Huawei: artificially suppressed external supply compounds Ascend's ecosystem lock-in faster than any subsidy. 12–24 month trajectory: China shifts from buying chips to buying architecture. EDA toolchains, HBM domestication, and Chiplet packaging close the loop by 2026. Nvidia's China revenue share compresses from roughly 25% to under 10%. The real cost isn't lost revenue—it's handing the competitor the single most valuable resource: time.